Kornimate/medical-research-clean huggingface dataset:
what happens to first trimester nuchal translucency

Conditions: Nuchal Translucency

Summary: first trimester nuchal translucency is a call point for genetic abnormalities and birth defects. nuchal translucency varies with lcc and therefore with gestational age as described by chung et al who created a 99th percentile curve of nuchal translucency versus lcc. the majority of centers use the 3.5 mm cutoff as the 99th percentile instead of using nuchal translucency based on lcc. the objective of this study is to compare the fate of nuchal hyperclites\> = 99th p but \ = 99th p and \<3.5mm that would have been sampled for a high combined risk for trisomy 21, and therefore to determine the benefit of a systematic sample. for hcn as well as the interest of performing an acpa that would not be performed on a sample with a high risk of trisomy 21.


Eligibility criteria:
inclusion criteria: nuchal translucency\> = 99th percentile exclusion criteria: - multiple pregnancies

Keywords: ultrasound abnormalities genetic abnormalities
application of 18f-psma pet / ct imaging in prostate specific membrane antigen positive tumor

Conditions: Malignancy

Summary: in this study, al18f-psma-bch pet/ct will be performed in patients with prostate specific membrane antigen positive tumor, to evaluate the tumour detection efficacy of al18f-psma-bch pet/ct.

al18f-psma-bch pet/ct will be performed on patients with suspected or clearly diagnosed psma positive-expressing tumors (including prostate cancer, transitional epithelial carcinoma, colon carcinoma, adenoid cystadenocarcinoma, mesothelioma, hepatocellular carcinoma, cholangiocellular carcinoma, multiple myeloma, etc.) , to evaluate the tumour detection efficacy of al18f-psma-bch pet/ct.

Eligibility criteria:
inclusion criteria: 1. patients with suspected or clearly diagnosed psma positive-expressing tumors, including prostate cancer, transitional epithelial carcinoma, colon carcinoma, adenoid cystadenocarcinoma, mesothelioma, hepatocellular carcinoma, cholangiocellular carcinoma, multiple myeloma, etc. 2. age is 18 or older; no gender limitation. 3. signed the informed consent. 4. willing and able to cooperate with all projects in this study. exclusion criteria: 1. patients with serious neurological diseases,or gastrointestinal tract disease, cardiovascular disease, liver disease, kidney disease, blood system disease, endocrine system disease, respiratory system disease, immune deficiency disease, etc 2. claustrophobia. 3. pregnant or lactation women. 4. received experimental drug or device within 1 month.

Keywords: malignancy prostate specific membrane antigen positive tumor
evaluation of long-term clinical acceptability and satisfaction with the ic-8 intraocular lens

Conditions: Cataract; Presbyopia

Summary: the purpose of this study is to evaluate the long-term clinical acceptability and overall satisfaction with the ic-8 iol at least 12 months post-iol implantation.

this will be a prospective, multi-center, non-interventional study in up to 80 patients previously implanted with an ic-8 iol contralaterally or bilaterally under the protocol acu-p14-029 at up to nine clinical sites within europe. the purpose of this study is to demonstrate the long-term clinical acceptability and overall satisfaction in patients implanted with the ic-8 iol. the primary study endpoint is binocular target-corrected near visual acuity (tcnva) of 20/32 or better in 85% or more patients at least 12 months post-implantation. the secondary study endpoint is overall satisfaction with postoperative vision in 85% or more patients reporting either satisfied or very satisfied at least 12 months post-implantation.

Eligibility criteria:
inclusion criteria: 1. patients previously implanted contralaterally or bilaterally with the ic-8 iol under the protocol acu-p14-029 and have had the iol implanted for a duration of at least 12 months and currently have the ic-8 iol in the eye. 2. availability, willingness, ability and sufficient cognitive awareness to comply with examination procedures at the study visit. 3. signed informed consent. exclusion criteria: 1. patients who have developed systemic or ocular pathology, not related to the iol that affected their best corrected distance visual acuity to be 0.8 decimal or worse as determined by diagnostic testing or investigator's medical judgment. -
study of ozurdex® treatment practice in patients with macular oedema due to retinal vein occlusion

Conditions: Macular Edema; Retinal Vein Occlusion

Summary: epidemiological study of ozurdex® in sites treating patients with retinal vein occlusion.


Eligibility criteria:
inclusion criteria: * macular oedema due to retinal vein occlusion exclusion criteria: * not living in metropolitan france
hand exercises for women with rheumatoid arthritis and impaired adl ability: an exploratory trial

Conditions: Rheumatoid Arthritis

Summary: the study examines whether hand exercise therapy as an add on to a compensatory intervention program focused on joint protection, assistive devices and alternative methods of doing will improve the performance of adl tasks requiring hand function in patients with rheumatoid arthritis (ra).


Eligibility criteria:
inclusion criteria: * female sex. * age ≥ 18. * diagnosis of rheumatoid arthritis (2). * involvement of the hands, due to minimum one tender wrist, metacarpophalangeal (mcp) or proximal interphalangeal (pip) joint in one of the hands. * be on stable medication for at least 3 months prior to participation. * self-reported decreased ability to perform personal and instrumental adl tasks involving the hands. exclusion criteria: * significant osteoarthritis of the hand assessed at the initial examination by the rheumatologist * hand surgery within 6 months of study participation * other pain condition involving muscles and/or joints, e.g. fibromyalgia. * prednisolon therapy, change in dose of biological agent or start of treatment with a new biological agent within the last 3 month before study start. * inability to understand the information or to speak danish * any other condition that in the opinion of the investigator or accessing rheumatologist puts an otherwise eligible participant at increased risk by participation or otherwise make the person unfit for participation.
casus: improved and quality assured collection of first-void urine

Conditions: Cervical Cancer; Cervical Intraepithelial Neoplasia; Human Papilloma Virus; HPV-Related Cervical Carcinoma; Urine

Summary: the goal of the overall casus project is to develop the first fully molecular integrated cervical cancer screening approach, based on first-void urine as an easily accessible and non-invasive source of biomarkers. in contrast to current screening modalities, the casus approach will identify women with clinically relevant disease in need of treatment using only a single sample that can be collected at home (one-step triage).

casus work package 1 (wp1): to accommodate for the detection of biomarkers in first-void urine, a next-generation first-void urine collection device is necessary, which includes internal process control, novel collector tubes for collection of smaller urine volumes, and integration of a non-toxic nucleic acid preservative. hereto, new generations of the colli-pee® (novosanis) first-void urine collector allowing collection of smaller volumes (colli-pee small volumes 4 and 10 ml) next to the 'standard' colli-pee fv5000 (20 ml) first-void urine collector will be developed and validated. the optimal urine volume needed for detection of host and viral biomarkers, as well as optimization of the nucleic acid preservative solution by introduction of a sample/extraction validation control (non-human dna internal control (dna ic)) will be evaluated by measuring the concentration of human dna, hpv dna, and the dna ic in all first-void urine samples using different dna extraction protocols.

Eligibility criteria:
inclusion criteria: * female * 18 years and older * women with a high-risk hpv positive test result within six months prior to study enrolment. * giving informed consent to the research team to contact his/her general practitioner and/or gynaecologist to access details of the participants hpv test results and cervical screening history. * able to understand the information brochure/what the study is about. exclusion criteria: * women that underwent hysterectomy or were treated for cervical (pre)cancer lesions within the previous six months prior to study enrolment. * participating in another interventional clinical study (where e.g. a medical device, drug, or vaccine is evaluated) at the same time of participating in this study. participation in another observational or low-interventional clinical study at the same time is allowed.

Keywords: biomarker first-void urine screening triage
study of deferasirox for treatment of transfusional iron overload in myelodysplastic patients

Conditions: Myelodysplastic Syndrome; Iron Overload

Summary: the purpose of this trial is to examine the safety and efficacy of deferasirox in patients with myelodysplastic syndrome (mds) and chronic iron overload from blood transfusions.

study entry requires a diagnosis of low or intermediate (int-1) risk mds per international prognostic scoring system (ipss) criteria and serum ferritin ≥ 1000 ng/ml. patients must have had at least 30 prior red blood cell transfusions. deferasirox will be administered at an initial dose of 20 mg/kg orally once per day. patient transfusion history and at least three complete blood count (cbc) values must be available for the 12 weeks prior to study registration for patients with mds and chronic iron overload from blood transfusions.

Eligibility criteria:
inclusion criteria: * male or female patients with low or intermediate (int-1) risk mds * patients can be either naïve to iron chelation or have had prior treatment with deferoxamine (dfo). * age greater than or equal to 18 years * availability of transfusion records for the 12 weeks prior to registration * a lifetime minimum of 30 previous packed red blood cell transfusions * availability of at least three cbc values (pretransfusion) during the 12 weeks prior to registration * serum ferritin: for entry into the screening period, serum ferritin ≥ 1000 ng/ml on at least two occasions, at least two weeks apart, during the prior year. serum ferritin ≥ 1000 ng/ml at screening via the central lab. * life expectancy ≥ 6 months * sexually active women must use an effective method of contraception, or must have undergone clinically documented total hysterectomy and/or oophorectomy, or tubal ligation or be postmenopausal (defined as amenorrhea for at least 12 months) * able to provide written informed consent exclusion criteria: * serum creatinine above the upper limit of normal * alanine aminotransferase (alt) \> 500 u/l during screening * clinical or laboratory evidence of active hepatitis b or c * urinary protein/creatinine ratio \> 0.5 mg/mg * history of hiv positive test result (elisa or western blot) * eastern cooperative oncology group (ecog) performance status \> 2 * patients with uncontrolled systemic hypertension * unstable cardiac disease not controlled by standard medical therapy * patients with a diagnosis of or history of clinically relevant ocular toxicity related to iron chelation * systemic diseases (cardiovascular, renal, hepatic, etc.) which would prevent study treatment * pregnancy or breast feeding * treatment with systemic investigational drug within the past 4 weeks or topical investigational drug within the past 7 days * other surgical or medical condition which might significantly alter the absorption, distribution, metabolism or excretion of study drug * history of non-compliance to medical regimens or patients who are considered potentially unreliable and/or not cooperative

Keywords: icl670 deferasirox iron chelation chelator desferal
comparison of hemodynamics between dexmedetomidine and propofol for sedation in patients with abdominal surgery

Conditions: Disorder; Mental, Sedative; Pain, Postoperative; Surgery

Summary: this is a single-blind randomized clinical trial. patients undergoing abdominal tumor surgery were recruited to participate in the study. apart from routine treatment in the surgical intensive care unit, the subjects were randomly divided into two groups: propofol group (group p) and dexmedetomidine group (group d) and received continuous intravenous infusion of propofol (infusion dosage range: 0.3 \~ 1.6 mg/kg/h) or dexmedetomidine (infusion dosage range: 0.1 \~ 0.7 mcg/kg/h) according to their assigned group. patients' hemodynamic status was monitored using a chest bioreactance technique, continuous non-invasive cardiac output and hemodynamic monitor at preset time points (time of recruitment \[0h\], 2, 4, 6, 12h and 24h). clinical data such as vital signs, hemodynamic parameters, laboratory results, fluid volume and drugs used were also recorded.


Eligibility criteria:
inclusion criteria: * non-emergent major abdominal tumor surgery with icu admission * the need of sedation during icu stay exclusion criteria: * age older than 99 years * age younger than 20 years * refractory arrhythmias * refractory shock status after resuscitation * new onset of myocardial infarction * severe heart failure or nyha 4 * apache score \> 30 when recruiting * severe liver cirrhosis or child b or c * organ transplantation within one year * pregnancy * allergic to propofol or dexmedetomidine
study of high density lipoprotein cholesterol (hdl-c)-raising mechanism of rosuvastatin (crestor™) by quantifying the key steps of reverse cholesterol transport (rct)

Conditions: Metabolic Syndrome; Dyslipidemia

Summary: the purpose of this study is to investigate the effect of treatment with rosuvastatin on the capacity of plasma to promote cholesterol efflux, which is the first and likely rate limiting step in reverse cholesterol transport.


Eligibility criteria:
inclusion criteria: * signed informed consent * males aged 45-65 * insulin resistance * central obesity * ldl-c \<6 mmol/l * plasma triglycerides \>=1.7 and ≤5.5 mmol/l * hdl-c ≤1.2 mmol/l. exclusion criteria: * total cholesterol \>7mmol/l * pre-existing cardiovascular disease, diabetes, proteinuria or renal failure

Keywords: metabolic syndrome dyslipaemia
a research study to show aprocitentan is efficacious and safe to treat patients with uncontrolled blood pressure and chronic kidney disease.

Conditions: Hypertension; Renal Insufficiency, Chronic

Summary: the purpose of this research study is to show the blood pressure lowering effect of aprocitentan, a new drug, when added to the background antihypertensive therapy in patients with uncontrolled blood pressure and chronic kidney disease (ckd) stage 3 or 4. participation in the research study will last up to 21 weeks (about 5 months).


Eligibility criteria:
inclusion criteria: * prior treatment with at least 2 anti-hypertensive medications, at optimal or best tolerated dose, of different pharmacological classes, including a diuretic, * participants with uncontrolled blood pressure (mean sitting systolic blood pressure of 140 mmhg or greater) and chronic kidney disease stage 3 or 4 (estimated glomerular filtration rate of at least 15 and below 60 ml/min/1.73m2 using the chronic kidney disease-epidemiology equation), * women of childbearing potential are eligible only if the following applies: * negative pregnancy test at the screening visit and at baseline (i.e., end of run-in period). * agree to undertake pregnancy tests during the study and up to 30 days after randomized study treatment discontinuation. * agree to use highly-effective methods of contraception up to at least 30 days after study treatment discontinuation. exclusion criteria: * mean sitting systolic blood pressure above 170 mmhg measured by "automated office blood pressure measurement" (aobpm), * mean sitting diastolic blood pressure above 105 mmhg measured by aobpm, * change in renal function requiring hospitalization, documented egfr decline of greater than 20% in the 3 months prior to the screening visit, dialysis in the 3 months before the screening visit, * planned dialysis or kidney transplant during the course of this study, * nephrotic syndrome defined as urine albumin-to-creatinine ratio above 3000 mg/g, * known and documented chronic heart failure.

Keywords: chronic kidney disease
reproducibility of interactive cariogram software versus manual caries risk assessment form

Conditions: Dental Caries

Summary: reproducibility of interactive cariogram software versus manual caries risk assessment form on clinician decision: observational study

a main factor for planning any preventive program is to accurately assess a person's risk of developing a caries. dental caries is a multifactorial disease and is affected by several factors, such as the patient's general health and diet, the amount and type of bacteria present in the oral cavity, salivary factors and exposure to fluoride. thus, caries risk assessment approaches should take into account risk implications from various factors that influence carious activity many caries risk assessment models had been developed to assess the caries for certain individual, this study will be carried out to measure the reproducibility between cambra and cariogram model to evaluate if one of them is enough to be used as they give the same result or not

Eligibility criteria:
inclusion criteria: * patients should be in range of 18-40 years old. patient should have good periodontal health exclusion criteria: * patient below 18 years and above 40 years old patient with periodontally affected teeth and mobility. patient with multiple extraction
role of bronchoscopy in early lung cancer screening of high risk population

Conditions: Lung Neoplasms

Summary: the purpose of this study is to determine the diagnostic yield of early lung cancer in high risk population, who smokes or has other risk factors, by different bronchoscopy,. furthermore, another purpose is to determine whether the different bronchoscopy are significant different in diagnosing early lung cancer.


Eligibility criteria:
inclusion criteria: * patient is over 40 years in age and is a heavy cigarette smoker.(smoking index is over 400) * patient has been coughing irritably for 2-3 weeks with a failed treatment and without obvious causes. * the nature of cough changes in a patient who has chronic respiratory disease. * patient has blood-stained sputum persistently or repeatedly without obvious causes. patient will be included if accorded with any item of above. exclusion criteria: * patient has dysrhythmia or cardiovascular disease that poses a risk during exercise. * patient has uncontrollable hypertension (sbp \> 180mmhg). * patient has severe organ dysfunction (shock, severe hepatic and renal dysfunction, massive hemorrhage of upper gastrointestine, diffuse intravascular coagulation(dic) and massive hemoptysis,etc). * patient has blood coagulation disorders (pt\>2 times the upper limit of normal(uln) or platelet(plt)\<50000/ul）. * patient has severe dyspnea. * patient is allergic to local anesthetic. * patient is unable to provide informed consent. * patient is not an appropriate candidate for or is unable to tolerate flexible bronchoscopy procedures. * patient has any disease or condition that interferes with completion of initial or follow-up assessments of the effectiveness endpoints. * patient has demonstrated unwillingness or inability to complete screening or baseline data collection procedures. * patient participated in a study of an investigational drug or device within the past 30 days prior to participation in this study, or is currently participating in another clinical study. * patient has pulmonary lesions suspected to be cancer from ct images. * female patient of childbearing potential has a positive result from a pregnancy test.

Keywords: lung neoplasms bronchoscopy early detection of cancer
pemetrexed in patients with soft tissue sarcoma

Conditions: Sarcoma

Summary: the aims of this trial are to evaluate the efficacy and tolerability of pemetrexed in patients with metastatic soft tissue sarcoma who have progressed after or during an anthracycline-based chemotherapy and to assess the toxicity profile

one therapy cycle takes a total of 3 weeks. on day 1, pemetrexed is intravenously administered. the dosage is 500 mg/m2 over a period of 10 minutes. a repetition of this procedure is performed on day 22

Eligibility criteria:
inclusion criteria: * histologically confirmed metastasized or locally inoperable soft tissue sarcoma * progression or relapse after previous cytostatic treatment with adriamycin and/or an ifosfamide containing chemotherapeutic substance * two-dimensionally measurable/evaluable tumor parameters (according to who-criteria) * previous radiotherapy is acceptable as long as the irradiated area does not include the only measurable lesion * patient compliance and geographic proximity, which ensure the possibility of adequate follow-up * life expectancy of more than 3 months * ecog \<= 2 * age at least 18 years * adequate bone marrow function at the initiation of therapy * adequate kidney function * patient consent * patient ability to consent exclusion criteria: * previous or concurrent irradiation of the indicator lesion * other concomitant tumor therapy * severe impairment in hepatic function * active infection * previous treatment with pemetrexed * second tumor within the past 5 years (excepting basal cell carcinoma, adequately treated carcinoma in situ of the uterine cervix, of the bladder urothelium or colon polyps including ptis and ptin) * severely symptomatic cardiovascular and cerebrovascular disease * hiv, active hepatitis b or c * dementia, cerebral stroke with cognitive deficits * kidney function \<= 79 ml/min (calculated according to mdrd): inability to interrupt treatment with nsaids/ass/cox-2 inhibitors 2 days prior to and following administration of pemetrexed. if a patient is taking an nsaid or salicylate with a long half-life it should not be taken five days prior to, on the day of or two days after application of pemetrexed. low dose acetyl salicylic acid administration is permitted (e.g. 100 mg/die.) there are no restrictions with kidney function greater than 80 ml/min. * inability or unwillingness to take folic acid, vitamin b12 or dexamethasone * pleural or pericardial exudate, ascites without a drain (3rd space) * time interval from the last course of chemotherapy \< 4 weeks * symptomatic cns-metastases * gravidity or lactation * women of reproductive age without reliable contraception if not the following applies: must be surgically sterile, postmenopausal, or compliant with a medically approved contraceptive regimen during and for 3 months after treatment * positive serum or urine pregnancy test * participation in another trial at the same time